• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?

作者信息

Boevé Liselotte M S, Vis André N

机构信息

Department of Urology, OLVG, Amsterdam, The Netherlands; Department of Urology, UMC Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.

Department of Urology, UMC Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.

出版信息

Eur Urol. 2019 Apr;75(4):e101-e102. doi: 10.1016/j.eururo.2018.11.034. Epub 2018 Nov 30.

DOI:10.1016/j.eururo.2018.11.034
PMID:30503181
Abstract
摘要

相似文献

1
Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
Eur Urol. 2019 Apr;75(4):e101-e102. doi: 10.1016/j.eururo.2018.11.034. Epub 2018 Nov 30.
2
Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: High-volume Disease Has a Different Standard of Care.
Eur Urol. 2019 Apr;75(4):e100. doi: 10.1016/j.eururo.2018.11.030. Epub 2018 Nov 23.
3
Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
Eur Urol. 2019 May;75(5):e131-e132. doi: 10.1016/j.eururo.2018.12.024. Epub 2019 Jan 4.
4
Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD Trial.
Eur Urol. 2019 Mar;75(3):e69-e70. doi: 10.1016/j.eururo.2018.11.008. Epub 2018 Nov 18.
5
Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD TrialUntil Randomised Controlled Trials Prove Different, Treat the Patient, Not His Imaging Results.回复阿什温·辛德、理查德·李、阿莉亚·阿米尼和斯科特·格拉泽给编辑的信，信的内容涉及：利塞尔洛特·M·S·博埃夫、马腾·C·C·M·胡尔肖夫、安德烈·N·维斯等人。在一项前瞻性随机临床试验中，单纯雄激素剥夺疗法与雄激素剥夺疗法联合前列腺同步放射疗法对原发性骨转移性前列腺癌患者生存的影响：来自HORRAD试验的数据。《欧洲泌尿外科杂志》2019年；75卷：410 - 418页：转移性前列腺癌确定性治疗的未来步骤：来自HORRAD试验的经验教训 直到随机对照试验证明情况不同之前，治疗患者，而非其影像学结果。
Eur Urol. 2019 Mar;75(3):e71-e72. doi: 10.1016/j.eururo.2018.11.007. Epub 2018 Nov 22.
6
Re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.回复：利塞尔otte M.S. 博埃夫、马尔滕 C.C.M. 胡尔绍夫、安德烈 N. 维斯等。前瞻性随机临床试验中，单纯雄激素剥夺疗法与雄激素剥夺疗法联合同期前列腺放疗对原发性骨转移性前列腺癌患者生存率的影响：HORRAD试验数据。《欧洲泌尿外科杂志》2019年；75卷：410 - 418页。
Eur Urol. 2019 May;75(5):e129-e130. doi: 10.1016/j.eururo.2018.12.025. Epub 2018 Dec 24.
7
Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.对戴安娜·A·卡斯蒂略 - 希门尼斯和埃尔内·A·加西亚 - 佩尔多莫致编辑的信的回复，信的主题为：尼兰詹·J·萨蒂亚纳森、巴德里纳特·R·科内蒂、费尔南多·阿拉里德 - 埃斯库德罗、内森·劳伦楚克、达米安·M·博尔顿、凯伦·M·孔茨。低风险前列腺癌男性主动监测策略的成本效益分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2018.10.055。经济分析的标准化报告应成为强制性要求。
Eur Urol. 2019 Jul;76(1):e10-e11. doi: 10.1016/j.eururo.2019.01.019. Epub 2019 Jan 18.
8
Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.回复：利亚姆·伯克、斯蒂芬·吉尔伯特、理查德·胡珀等人。生活方式改变对接受晚期前列腺癌长期雄激素剥夺治疗的久坐男性特定疾病生活质量的改善作用：一项随机对照试验。《欧洲泌尿外科杂志》2014年；65：865 - 872；回复：丹尼尔·A·加尔瓦奥、奈杰尔·斯普里、詹姆斯·德纳姆等人。一项针对接受过雄激素抑制和放疗的前列腺癌男性进行的为期一年的多中心随机对照试验，该试验以运动训练改善身体机能为目标（来自TROG 03.04 RADAR研究）。《欧洲泌尿外科杂志》2014年；65：856 - 864；回复：南希·L·基廷、刘庞祥、A·詹姆斯·奥马利、斯蒂芬·J·弗里德兰、马修·R·史密斯。前列腺癌男性糖尿病患者中的雄激素剥夺治疗与血糖控制。《欧洲泌尿外科杂志》2014年；65：816 - 824；回复：克里斯蒂娜·G·耶斯佩森、梅特·诺尔加德、迈克尔·博勒。前列腺癌治疗中的雄激素剥夺治疗与心肌梗死和中风风险：一项基于丹麦全国人口的队列研究。《欧洲泌尿外科杂志》2014年；65：704 - 709。
Eur Urol. 2014 Sep;66(3):e51-2. doi: 10.1016/j.eururo.2014.04.018. Epub 2014 May 10.
9
Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.对皮鲁斯·加贾尔和托马斯·维格尔致编辑的信的回复，信的主题为：阿卜杜勒努尔·纳比德、娜塔莉·卡里尔、安德烈 - 居伊·马丁等人。高危前列腺癌雄激素剥夺治疗的持续时间：一项随机III期试验。《欧洲泌尿外科杂志》2018年；74卷：432 - 431页。
Eur Urol. 2019 Mar;75(3):e63. doi: 10.1016/j.eururo.2018.10.029. Epub 2018 Oct 26.
10
Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
Eur Urol. 2019 Mar;75(3):e61-e62. doi: 10.1016/j.eururo.2018.10.030. Epub 2018 Oct 26.